Physician profile
Mohammed Alattar
NPI 1699881680
$1,480.71
in general payments reported to CMS, 2019-2025
24 companies · $29.26 in 2025
The $29.26 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $584 · 2020: $571 · 2021: $127 · 2022: $109 · 2023: $60.17 · 2025: $29.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $89.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $89.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $267.76 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.76 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $145.47 | 2019-2025 | Tezspire |
| Pulmonx Corporation | $125.00 | 2020 | |
| Mylan Specialty L.P. | $100.90 | 2019-2023 | Yupelri |
| Sunovion Pharmaceuticals INC. | $85.77 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $85.39 | 2019-2020 | |
| Philips North America LLC | $70.76 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $63.46 | 2020 | |
| Genzyme Corporation | $62.22 | 2019-2021 | |
| Pfizer INC. | $44.05 | 2021 | |
| Mallinckrodt Enterprises LLC | $37.92 | 2019 | |
| Harmony Biosciences LLC | $33.53 | 2020 | |
| Insmed, INC. | $30.40 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $29.26 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Portola Pharmaceuticals, LLC | $19.71 | 2019 | |
| United Therapeutics Corporation | $18.43 | 2019 | |
| Covidien LP | $17.38 | 2019 | |
| Inspire Medical Systems, INC. | $17.15 | 2023 | Inspire |
| Genentech USA, INC. | $16.34 | 2019 | |
| Baxter Healthcare | $14.92 | 2022 | |
| Grifols USA, LLC | $14.45 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.27 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $11.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Alattar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.